Inflammatory cytokines and systemic-onset juvenile idiopathic arthritis

Modern Rheumatology

Volumn 14, Issue 1, 2004, Pages 12-17

  Yokota, Shumpei ^a   Miyamae, Takako ^a   Imagawa, Tomoyuki ^a   Iwata, Naomi ^a,b   Katakura, Shigeki ^a   Mori, Masaaki ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b AICHI CHILDREN'S HEALTH AND MEDICAL CENTER   (Japan)

Author keywords

Antirheumatic drug; Cytokine; Cytokine inducible proteins; Inflammation; Juvenile idiopathic arthritis (JIA)

Indexed keywords

ANTIRHEUMATIC AGENT; CORTICOSTEROID; CYCLOSPORIN; CYTOKINE; CYTOTOXIC AGENT; GLYCOPROTEIN GP 130; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 6 RECEPTOR ANTIBODY; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; UNCLASSIFIED DRUG;

ANAPHYLAXIS; ARTHRITIS; CATARACT; CLINICAL FEATURE; CLINICAL TRIAL; COMPLEX FORMATION; CUSHINGOID SYNDROME; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG MEGADOSE; ERYTHEMA; FEVER; FRACTURE; GROWTH RETARDATION; HOMEOSTASIS; HUMAN; INFECTION SENSITIVITY; INFLAMMATION; INFLAMMATORY INFILTRATE; JUVENILE RHEUMATOID ARTHRITIS; LONG TERM EXPOSURE; MACROPHAGE ACTIVATION; NAUSEA; NONHUMAN; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; RASH; REVIEW; SYSTEMATIC REVIEW; SYSTEMIC DISEASE; TRANSGENIC MOUSE; TUBERCULOSIS;

EID: 20444397433     PISSN: 14397595     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10165-003-0259-0     Document Type: Review

References (46)

1. Fink CW. Proposal for the development of classification criteria for idiopathic arthritides of childhood. J Rheumatol 1995;22:1566-9.
2. Still GF. On a form of chronic joint disease in children. Med Chir Trans 1897;80:1-13.
3. Cassidy JT, Petty RE. Chronic arthritis. In: Cassidy JT, Petty RE, editors. Textbook of pediatric rheumtology. 4th ed. Philadelphia: W.B. Sanders; 2001. pp. 214-321.
4. Fujikawa S, Okuni M. Clinical analysis of 570 cases with juvenile rheumatoid arthritis: Results of a nationwide retrospective survey in Japan. Acta Paediatr Jpn 1997;39:245-9.
5. Sawhney S, Woo P, Murray KJ. Macrophage activation syndrome: A potentially fatal complication of rheumatic disorders. Arch Dis Child 2001;85:421-6.
6. Imagawa T, Katakura S, Mori M, Aihara Y, Mitsuda T, Yokota S. A case of macrophage activation syndrome developed with systemic juvenile rheumatoid arthritis. Ryumachi 1997;37:487-92.
7. Grom AA, Passo O. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis. J Pediatr 1996;129:630-2.
8. De Benedetti F, Martini A. Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease? J Rheumatol 1998;25:203-7.
9. Nishimoto N, Kishimoto T, Yoshizaki K. Anti-interleukin-6 receptor antibody treatment in rheumatic disease. Ann Rheum Dis 2000;59 Suppl 1:21-7.
10. Choy EHS, Isenberg DA, Garrood T, Farrow S, Ioannou Y, Bird H, et al. The therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis. Arthritis Rheum 2002;46:3143-50.
11. Nishimoto N, Sasai M, Shima Y, Nakagawa M, Matsumoto T, Shirai T, et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 2000;95:56-61.
12. Iwamoto M, Nara H, Hirata D, Minota S, Nishimoto N, Yoshizaki K. Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease. Arthritis Rheum 2002;3388-9.
13. Prahalad S, Bove KE, Dickens D, Lovell DJ, Grom AA. Etanercept in the treatment of macrophage activation syndrome. J Rheumatol 2001;28:2120-4.
14. Mouy R, Stephan JL, Pillet P, Haddad E, Hubert P, Prieur AM. Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: Report of five cases. J Pediatr 1996;129:750-4.
15. Tran TN, Eubanks SK, Schaffer KJ, Zhou CY, Linder MC. Secretion of ferritin by rat hepatoma cells and its regulation by inflammatory cytokines and iron. Blood 1997;90:4979-86.
16. Vangri P. Interferon-gamma-inducible genes in primary glial cells of the central nervous system: Comparisons of astrocytes with microglia and Lewis with Brown Norway rats. J Neuroimmunol 1995;56:35-43.
17. Toshitani K, Braud V, Browning MJ, Murray N, McMichael AJ, Bodmer WF. Expression of a single-chain HLA class I molecule in a human cell line: presentation of exogenous peptide and processed antigen to cytotoxic T lymphocytes. Proc Natl Acad Sci USA 1996;93:236-40.
18. Tapalaga D, Tiegs G, Angermuller S. NFkappaB and caspase-3 activity in apoptotic hepatocytes of galactosamine-sensitized mice with TNFalpha. J Histochem Cytochem 2002;50:1599-609.
19. Bradham CA, Qian T, Streetz K, Trautwein C, Brenner DA, Lemasters JJ. The mitochondrial permeability transition is required for tumor necrosis factor alpha-mediated apoptosis and cytochrome c release. Mol Cell Biol 1998;18:6353-64.
20. Lemasters JL, Nieminen A-L, Qian T, Trost LC, Elmore SP, Nishimura Y, et al. The mitochondrial permeability transition in cell death: A common mechanism in necrosis, apoptosis and autophagy. Biochem Biophys Acta 1998;1366:177-96.
21. Murr C, Widner B, Wirleitner D, Fuchs D. Neopterin as a marker for immune activation. Curr Drug Metab 2002;3:175-87.
22. Behera AK, Kumar M, Lockey RF, Mohapatra SS. 2′-5′- Oligoadenylate synthetase plays a critical role in interferongamma inhibition of respiratory syncytial virus infection of human epithelial cells. J Biol Chem 2002;277:25601-8.
23. Hirota H,Yoshida K, Kishimoto T, Taga T. Continuous activation of gp130, a signal-transducing receptor component for interleukin-6-related cytokines, causes myocardial hypertrophy in mice. Proc Natl Acad Sci USA 1995;92:4862-6.
24. Prieur A-M, Roux-Lombard P, Dayer J-M. Dynamics of fever and the cytokine network in systemic juvenile arthritis. Rev Rheum 1996;63:163-70.
25. Harre EM, Roth J, Pehl U, Kueth M, Gerstberger R, Hubschle T. Selected contribution: Role of IL-6 in LPS-induced nuclear STAT 3 translocation in sensory circumventricular organs during fever in rats. J Appl Physiol 2002;92:2657-66.
26. Jenkins BJ, Quilici C, Roberts AW, Grail D, Dunn AR, Ernst M. Hematopoietic abnormalities in mice deficient in gp130-mediated STAT signaling. Exp Hematol 2002;30:1248-56.
27. Lieskovska J, Guo D, Derman E. IL-6 overexpression brings about growth impairment potentially through a GH receptor defect. Growth Hormone IGF Res 2002;12:388-98.
28. Lieskovska J, Guo D, Derman E. Growth impairment in IL-6-overexpressing transgenic mice is associated with induction of SOCS3 mRNA. Growth Hormone IGF Res 2003;13:26-35.
29. De Benedetti F, Massa M, Robbioni P, Ravelli A, Burgio GR, Martini A. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 1991;34:1158-63.
30. De Benedetti F, Massa M, Pignatti O, Albani S, Novick D, Martini A. Serum soluble interleukin-6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J Clin Invest 1994;93:2114-9.
31. Woo P. Cytokines and juvenile idiopathic arthritis. Curr Rheumatol Rep 2002;4:452-7.
32. Rooney M, David J, Symons J, Di Giovine F, Varsani H, Woo P. Inflammatory cytokine responses in juvenile chronic arthritis. Br J Rheumatol 1995;34:454-60.
33. Keul R, Heinrich PC, Muller-Newen G, Muller K, Woo P. A possible role for soluble IL-6 receptor in the pathogenesis of systemic onset juvenile chronic arthritis. Cytokine 1998;10:729-34.
34. Taga T. Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol 1997;15:797-819.
35. Ishihara K, Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Rev 2002; 13:357-68.
36. Taga T. gp130, a shared signal transducing receptor component for hematopoietic and neuropoietic cytokines. J Neurochem 1996;67: 1-10.
37. Murakami M, Hibi M, Nakagawa N, Nakagawa T, Yasukawa K, Yamanishi K, et al. IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science 1993;260:1808-10.
38. Sengupta TK, Talbot ES, Scherle PA, Ivashkiv LB. Rapid inhibition of interleukin-6 signaling and Stat-3 activation mediated by mitogen-activated protein kinases. Proc Natl Acad Sci USA 1998;95:11107-12.
39. Nicola NA, Greenhalgh CJ. The suppresors of cytokine signaling (SOCS) proteins: Important feedback inhibitors of cytokine action. Exp Hematol 2000;28:1105-12.
40. Naka T, Nishimoto N, Kishimoto T. The paradigm of IL-6: From basic science to medicine. Arthritis Res 2002;4 Suppl 3:S233-42.
41. Yin T, Taga T, Tsang ML, Yasukawa K, Kishimoto T, Yang YC. Involvement of interleukin-6 signal transducer gp130 in interleukin-11-mediated signal transduction. J Immunol 1993;151:2555-61.
42. Liu J, Modrell B, Aruffo A, Marken JS, Taga T, Yasukawa K, et al. Interleukin-6 signal transducer gp130 mediates oncostatin M signaling. J Biol Chem 1992;267:763-66.
43. Van Zaanen HC, Lokhorst HM, Aarden LA, Rensink HJ, Warnaar SO, Van Oers MH. Chimaeric anti-interleukin-6 monoclonal antibodies in the treatment of advanced multiple mueloma: A phase I dose-escalating study. Br J Haematol 1998;102:783-90.
44. Durandy A. Anti-B cell and anti-cytokine therapy for the treatment of post-transplant lymphoproliferative disorder: Past, present, and future. Transpl Infect Dis 2001;3:104-7.
45. Sato K, Tsuchiya M, Saldanha J, Koishihara Y, Ohsugi Y, Kishimoto T. Reshaping a human antibody to inhibit interleukin-6- dependent tumor cell growth. Cancer Res 1993;53:851-6.
46. Katsume A, Saitou H, Yamada Y, Yorozu K, Ueda O, Akamatsu K, et al. Anti-interleukin-6 (IL-6) receptor antibody suppresses Castleman's-disease-like symptoms emerged in IL-6 transgenic mice. Cytokine 2002;20:304-11.